The global nucleic acid therapeutics CDMO market is expected to reach $4,463.7 Million by 2030, with a CAGR of 11.09 % during the forecast period 2021-2030.
The increasing willingness to outsource drug development to the CDMOs, and the rising need for pharmaceuticals have resulted in the expansion of the global market for nucleic acid therapeutics CDMO.
The exponential rise in the application of nucleic acid therapeutics CDMO market on the global level has created a buzz among companies to invest in the manufacturing of nucleic acid-based therapies. In the past five years (July 2017-July 2021), the nucleic acid therapeutics CDMO market witnessed approximately 31 notable key developments. These included one product launch, two regulatory and legal activities, three mergers and acquisitions, 24 synergistic developments (partnerships, collaborations, agreements, and business expansion activities).